ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

IMM Immupharma Plc

1.15
-0.005 (-0.43%)
13 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma Plc LSE:IMM London Ordinary Share GB0033711010 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.005 -0.43% 1.15 1.02 1.255 1.27 1.27 1.27 733,994 16:35:03
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Finance Services 0 -2.92M -0.0070 -1.81 4.81M
Immupharma Plc is listed in the Finance Services sector of the London Stock Exchange with ticker IMM. The last closing price for Immupharma was 1.16p. Over the last year, Immupharma shares have traded in a share price range of 0.83p to 2.90p.

Immupharma currently has 416,440,000 shares in issue. The market capitalisation of Immupharma is £4.81 million. Immupharma has a price to earnings ratio (PE ratio) of -1.81.

Immupharma Share Discussion Threads

Showing 39126 to 39149 of 39200 messages
Chat Pages: 1568  1567  1566  1565  1564  1563  1562  1561  1560  1559  1558  1557  Older
DateSubjectAuthorDiscuss
31/7/2024
12:43
So it looks like a full scale ramp is ongoing…
nobbygnome
31/7/2024
10:37
Well I’ve made some good money from Incanthera so perhaps I should now be lauding Tim as a biotech guru….
nobbygnome
31/7/2024
10:37
Good lad. You know it makes sense.
socionomics
31/7/2024
10:36
Ok I’ll rush out and buy some then….😆;
nobbygnome
31/7/2024
10:34
I feel it in my bones Nobby.
socionomics
31/7/2024
10:32
Now might be a good time to buy IMM.
socionomics
05/6/2024
06:59
This is where future funding will come from .... ;-)

GLA SR

The warrant deeds (between the Company and the respective counter-parties - the holders of warrants) have been varied, such that the exercise price of the 2021 Warrants and 2022 Warrants is reduced from 11 pence and 5.5 pence respectively to 2 pence.


The 2021 Warrants and 2022 Warrants will then be exercisable at the earlier of (i) the five day volume weighted average price of Ordinary Shares attaining 4 pence or (ii) 12 months following First Admission or (iii) a takeover offer is announced for the Company. The reduction in the warrant exercise prices was agreed with all the warrant holders and from the Company's perspective, there will be a higher probability of receiving additional funding from the exercise of these warrants as the share price appreciates and the warrants are 'in the money'.

stockriser
03/6/2024
13:57
thiopia - it's not nonsense at all.

I never said it was the ONLY way to fund a warrant exercise.

But it's more sensible & cheaper than any financial institution route, given IMM's current cash position. Especially as they can STILL retain a fair stake in Incanthera by exercising their warrants, whilst adding around £800k to their cash reserves.

lord loads of lolly
03/6/2024
12:31
What is this nonsense about funding a warrant exercise ? There are plenty of financial institutions who could provide financing for it.
thiopia
03/6/2024
10:46
Presumably today's sale of IMM's entire holding in Incanthera, netting c£1.5m is to fund the c7.3 million warrants at 9.5p before they expire on 6 September 2024?

7.3m Incanthera warrants would cost them around £694k. Assuming Incanthera's share price holds at around 20p, IMM can double their money on the warrants overnight & still have around £800k left over.

lord loads of lolly
04/5/2024
15:47
I wasn't aware of this - may be worth keeping an eye on for holders, although a good way from commercial release:



People with autoimmune disorders don’t usually get to talk about a cure. There’s symptom management, hopeful periods of remission often followed by relapses, but rarely a lasting fix for the way their immune system attacks healthy cells. If the immune system is an army, then those with conditions like lupus, multiple sclerosis, or rheumatoid arthritis are often fighting a never-ending war of friendly fire.

But over the last few years, researchers in Germany have begun testing the potential of CAR-T therapy — a cutting-edge cancer treatment in which a patient’s immune T cells are genetically modified in a lab to better attack disease targets — to help those with autoimmune disorders. Their latest findings, published Wednesday in the New England Journal of Medicine, provide evidence that has led experts to consider, tentatively, using the c-word.

In a study of 15 patients — eight with lupus, four with systemic sclerosis (scleroderma), and three with idiopathic inflammatory myositis, a rare muscle disease — researchers eliminated or reduced symptoms and disease biomarkers with a single infusion of CAR-T cells designed to target B cells, immune cells that play a key role in driving autoimmunity. There were no relapses among lupus patients, who were monitored for up to two years after treatment. The myositis and sclerosis patients, who had shorter-term follow-up (usually about three to six months but up to a year) saw their symptoms significantly lessen.

[...]

supernumerary
07/4/2024
10:37
Nobbyg-What do you consider is the time range for obtaining the patents mentioned in the last RNS? Do you think that this could adversely affect the time range for the Lupus trial commencing?

ATB

clintdavid1
25/3/2024
12:35
The Incanthera direct holding must be worth gbp1.5m after todays rise plus 7.3m warrants which can be exercised anytime, so warrants presumably worth another gbp1.25m approx. This is what i call hidden value on the balance sheet.
rimau1
25/3/2024
12:30
Good to see the rise for the LTHs here and the recent punters. It is somewhat ironic that the rise is due to the success of another company…but beggars can’t be choosers.
nobbygnome
25/3/2024
12:23
Nice and quiet on here at moment, steady as she blows,when will all the Muppets arrive slagging it off lol GLA
courty2
25/3/2024
09:49
Money moving to APH [LSE] , excellent profitable healthcare company
blackhorse23
22/3/2024
15:18
Still life in the old dog yet.
tewkesbury
15/3/2024
14:00
stockriser - the announcement of no further dilution for now was, on the face of it, undoubtedly good news. It calmed market nerves & marked a turning point in share price direction.

That said, past pronouncements - notably from Tim M - have often proved unreliable. Also, any sale of IMM’s Incanthera holding would, in effect, just be dilution by the back door. Hopefully a commercial deal will come along before then to make this option unnecessary.

lord loads of lolly
15/3/2024
11:35
...and it's worth reminding ourselves. This isn't a one-trick-pony. Many potential game changers in the pipeline. Multiple shots on goal.
the imperialist
15/3/2024
11:28
TI - Totally agree with you, Mcap is ridiculous for this Co., with so much potential and also as you say no further dilution.
stockriser
15/3/2024
11:25
The Co. confirmed no further dilution. For me that calls the bottom. The upside here is huge.
the imperialist
15/3/2024
11:24
Many think this may drop back a bit so they can get in lower - Hmmm, not so sure myself.

GLA SR

stockriser
15/3/2024
09:53
Me too, but trying to keep this under the RADAR.
the imperialist
15/3/2024
09:30
Good morning
More interest in these today with a decent share price gain.
No new published news though
I hold few.

maytrees
Chat Pages: 1568  1567  1566  1565  1564  1563  1562  1561  1560  1559  1558  1557  Older